Navigation Links
Watson and Richter Announce Exclusive License Agreement for Esmya™
Date:12/16/2010

MORRISTOWN, N.J., and BUDAPEST, HUNGARY, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) ("Watson") and Gedeon Richter Plc ("Richter") today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.  In European studies, Esmya™ has been shown to be an effective and safe treatment for uterine fibroids (myoma), a condition that affects millions of women worldwide. The product is currently in late stage development in Europe and Watson expects to initiate U.S. Phase III clinical studies in 2011.

Under terms of the agreement, Watson will pay PregLem a $17 million license fee and will pay royalties based on sales in the U.S. and Canada. Watson will make additional payments based on the achievement of certain regulatory milestones. The companies will also collaborate on additional Esmya™ formulations, jointly sharing the development costs.

"Esmya™ represents a significant strategic addition to our portfolio of women's health products and is potentially the first effective treatment for uterine fibroids in more than 20 years," said Paul Bisaro, Watson's Chief Executive Officer.  "The agreement enables us to maximize our expertise in developing, registering and commercializing significant therapeutic advances in diseases treated by OB/GYNs.  It also forms the foundation for us to further develop a franchise of products and indications in the uterine fibroid category.  We look forward to further expanding our relationship with PregLem and Gedeon Richter for future opportunities between our companies."

"I am pleased with the agreement concluded with Watson, as their specialty knowledge and marketing
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:7/28/2015)... Raleigh, NC (PRWEB) , ... July 28, 2015 ... ... others cancers are more common in shipbreaking workers than they are in the ... Click here to read it now. , Researchers at Taiwan’s National ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's ... is that cancer, heart attack, and stroke are treatable, but there is little an ... do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... Every ... professionals or to use extreme caution when lighting fireworks in their own neighborhoods. Unfortunately, ... and discussed in a July 3, 2015 USA Today article " Eye Injuries Caused ...
(Date:7/28/2015)... ... 28, 2015 , ... A June 3, 2015 article ... Injury" discussed baseball player David Wright’s spinal stenosis injury and his chances of ... by degenerative changes in the spine, rather than congenital, which is good news ...
(Date:7/28/2015)... ... , ... Most employers have been using multi-tier prescription drug plans for many ... significant increase in the use of 4-tier plans, which typically cover the highest cost ... is expected to continue, according to UBA. , UBA’s survey finds that, since 2009, ...
Breaking Medicine News(10 mins):Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... By Maureen Salamon HealthDay Reporter , WEDNESDAY, ... created equal, with women and men facing different heart risks ... a new study suggests. Analyzing the results of coronary ... blockages -- in 480 patients with acute chest pain, scientists ...
... by researchers at Cleveland Clinic published findings that indicate ... pain for an extended period of time. Fibronectin ... the survival, growth and communication of neurons in the brain ... animal model, that an injection of fibronectin into the spinal ...
... About 40 percent of young adults who,ve attempted suicide made ... thoughts and behavior may begin much younger than previously believed, ... ongoing survey, University of Washington researchers asked almost 900 young ... attempts. Nearly 9 percent (78) of the participants said ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) -- Eating ... may boost brain health and lower the risk for mild ... The study authors found that eating baked and broiled ... matter neurons, strengthening them in areas of the brain deemed ...
... that world renowned neurosurgeon R. Michael Scott, MD, ... Distinguished Service Award. Given by the American Association ... the award is the highest honor given by ... advanced the field of pediatric neurosurgery. Alan Cohen, ...
... NY Scientists investigating the interactions, or binding patterns, ... the entire genome in normal human cells have turned ... The distinct binding patterns reflect differences in the chromatin ... be important for understanding the function of the tumor ...
Cached Medicine News:Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 2Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 3Health News:Cleveland researchers find possible breakthrough to relieve pain following spinal cord injury 2Health News:Many Suicidal Teens Make First Try Before High School 2Health News:Non-Fried Fish Might Help Ward Off Alzheimer's: Study 2Health News:Non-Fried Fish Might Help Ward Off Alzheimer's: Study 3Health News:R. Michael Scott, M.D., receives the Franc D. Ingraham Distinguished Service Award 2Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 2Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 3Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 4
... The DNA Expert: Detection of PCR, cDNA and ... an optimal microplate reader for a variety applications ... The instrument is suitable to handle assays in ... PCR tubes Cuvettes ...
... From solution to cell based assays, in ... non-isotopic method of detection, Fusion is the ... plus the capability to use the AlphaScreen ... modes in one system: Reads AlphaScreen ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
Medicine Products: